Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CNMD
CNMD logo

CNMD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
38.700
Open
38.010
VWAP
37.34
Vol
387.17K
Mkt Cap
1.11B
Low
36.550
Amount
14.46M
EV/EBITDA(TTM)
10.56
Total Shares
30.11M
EV
1.93B
EV/OCF(TTM)
13.55
P/S(TTM)
0.83
CONMED Corporation is a medical technology company, which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.
Show More

Events Timeline

(ET)
2026-04-29
16:40:00
CONMED Q1 Revenue of $317M Beats Expectations
select
2026-04-29
16:40:00
Company Narrows FY26 Revenue View to $1.35B-$1.375B
select
2026-01-28 (ET)
2026-01-28
19:40:00
Meta and IBM Shares Rise 7% After Earnings
select
2026-01-28
16:10:00
Sees FY26 Revenue of $1.345B-$1.375B
select
2026-01-28
16:10:00
CONMED Q4 Revenue $373.2M Exceeds Consensus
select
2026-01-08 (ET)
2026-01-08
17:00:00
Conmed CFO Todd Garner to Depart on March 15
select

News

seekingalpha
9.5
04-30seekingalpha
CONMED Q1 2026 Earnings Call Insights
  • Strategic Divestiture: In Q1, CONMED completed the divestiture of certain GI products, strategically reallocating resources to focus on higher growth and higher-margin offerings, thereby enhancing execution and long-term shareholder value.
  • Sales Performance Review: Total sales for the quarter were $317 million, a 1.3% year-over-year decline; however, excluding the impact of GI products, sales increased by 3.8% year-over-year, demonstrating resilience and growth potential in core operations.
  • Profitability Analysis: Adjusted net income stood at $27.1 million, down 8.5% year-over-year, with adjusted EPS at $0.89, a 6.3% decrease; despite rising financing costs, the company maintains its full-year EPS guidance, reflecting management's confidence.
  • Upgraded Future Outlook: CONMED raised its organic growth expectation for 2026 to 5.0%-6.5% and anticipates Q2 revenue between $336 million and $340 million, indicating a positive outlook on market demand.
NASDAQ.COM
9.5
04-29NASDAQ.COM
CONMED Reports Doubling of Q1 Profit, Raises Growth Outlook
  • Profit Doubling: CONMED's Q1 net income surged to $13.8 million, more than doubling from $6.0 million last year, indicating successful cost control and margin improvement despite a slight decline in sales.
  • Slight Sales Decline: The company's net sales fell 1.3% year-over-year to $317.0 million, primarily impacted by a $15.5 million drop from exiting certain gastroenterology products, although international revenue rose 4.7%, showcasing resilience in global markets.
  • Upgraded Full-Year Outlook: CONMED raised its 2026 organic revenue growth forecast to 5.0% to 6.5%, with reported revenue expected between $1.35 billion and $1.375 billion, reflecting strong confidence in future growth.
  • Strategic Focus on High-Growth Areas: CEO Patrick J. Beyer emphasized the company's commitment to concentrating resources on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair, aiming to drive long-term sustainable growth.
seekingalpha
9.5
04-29seekingalpha
CONMED Q1 Earnings Beat Expectations, Full-Year Outlook Raised
  • Earnings Beat: CONMED reported a Q1 non-GAAP EPS of $0.89, exceeding expectations by $0.07, indicating strong market performance and boosting investor confidence.
  • Slight Revenue Decline: Q1 revenue stood at $317 million, down 1.3% year-over-year but still beating expectations by $6.39 million, demonstrating the company's ability to maintain relatively stable revenue in a competitive environment.
  • Upgraded Full-Year Outlook: Based on Q1 performance, the company raised its 2026 organic revenue growth forecast to 5.0% to 6.5%, up from the previous range of 4.5% to 6.0%, reflecting management's confidence in future growth.
  • Positive Forex Impact: The updated revenue outlook incorporates a favorable foreign exchange impact of 40 to 50 basis points, showcasing the company's adaptability in global markets, while gastroenterology product revenue is expected to decrease to $14.5 million to $17.5 million, highlighting the necessity of strategic adjustments.
NASDAQ.COM
2.0
04-06NASDAQ.COM
CONMED Shares Enter Oversold Territory
  • Oversold Signal: CONMED Corp (CNMD) saw its RSI drop to 29.4 during Monday's trading, indicating the stock has entered oversold territory, potentially attracting bullish investors looking for buying opportunities.
  • Price Fluctuation: The stock price hit a low of $33.85, nearing its 52-week low of $33.21, suggesting that the recent heavy selling pressure is beginning to wane.
  • Market Comparison: Compared to the current RSI of 47.6 for the S&P 500 ETF (SPY), CNMD's oversold condition may indicate an impending market sentiment reversal, prompting investors to watch for potential rebound opportunities.
  • Historical Performance: With a 52-week high of $61.08 and a current trading price of $34.08, CNMD shows potential for value recovery after significant volatility, making it a stock to monitor for future gains.
seekingalpha
4.0
03-17seekingalpha
Conmed Corporation Stock Downgraded by Piper Sandler
  • Rating Downgrade Impact: Piper Sandler downgraded Conmed (CNMD) from Overweight to Neutral, citing a lack of catalysts to spark investor interest, leading to a stock decline on Tuesday that reflects market concerns about the company's future growth.
  • Demand Slowdown Analysis: Analyst Matt O'Brien noted that while Conmed's AirSeal robotic solution did not completely implode after Intuitive Surgical (ISRG) launched a competing product, poor messaging and execution missteps have negatively impacted the stock for two years.
  • Market Outlook Comparison: O'Brien concurrently upgraded Tandem Diabetes (TNDM) to Overweight, indicating that he sees better prospects in other SMID-cap MedTech companies, which further exacerbates the negative outlook for Conmed.
  • Lack of Catalysts: Despite Conmed's attractive valuation and M&A capacity, the analyst believes there are currently no clear catalysts to turn the company's situation around, reflecting a pessimistic sentiment regarding its future growth potential.
NASDAQ.COM
2.0
03-10NASDAQ.COM
CONMED Shares Enter Oversold Territory
  • Oversold Signal: CONMED Corp (CNMD) saw its RSI drop to 29.95 during Tuesday's trading, indicating the stock has entered oversold territory, suggesting that the recent heavy selling may be exhausting, prompting investors to look for buying opportunities.
  • Price Fluctuation: CNMD shares hit a low of $38.42, with the current trading price at $38.46, highlighting significant volatility compared to its 52-week low of $35.37 and high of $63.69, reflecting market sentiment.
  • Market Comparison: In contrast to the S&P 500 ETF (SPY) RSI of 43.4, CNMD's oversold condition may attract bullish investors, especially during potential shifts in market sentiment.
  • Investment Opportunity: Given the oversold signal, investors might consider buying CNMD shares as they rebound, aiming to capitalize on potential recovery opportunities and enhance portfolio returns.
Wall Street analysts forecast CNMD stock price to rise
5 Analyst Rating
Wall Street analysts forecast CNMD stock price to rise
1 Buy
4 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
41.00
Averages
50.00
High
55.00
Current: 0.000
sliders
Low
41.00
Averages
50.00
High
55.00
JPMorgan
Neutral
downgrade
$43 -> $40
AI Analysis
2026-04-30
Reason
JPMorgan
Price Target
$43 -> $40
AI Analysis
2026-04-30
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Conmed to $40 from $43 and keeps a Neutral rating on the shares.
Wells Fargo
Equal Weight
maintain
$42
2026-03-18
Reason
Wells Fargo
Price Target
$42
2026-03-18
maintain
Equal Weight
Reason
Wells Fargo initiated coverage of assumed with an Equal Weight rating and $42 price target. The firm is maintaining the current rating, price target, and estimates.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CNMD
Unlock Now

Valuation Metrics

The current forward P/E ratio for Conmed Corp (CNMD.N) is 27.17, compared to its 5-year average forward P/E of 25.62. For a more detailed relative valuation and DCF analysis to assess Conmed Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
25.62
Current PE
27.17
Overvalued PE
36.27
Undervalued PE
14.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
14.84
Current EV/EBITDA
14.21
Overvalued EV/EBITDA
19.48
Undervalued EV/EBITDA
10.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.23
Current PS
0.77
Overvalued PS
3.20
Undervalued PS
1.26

Financials

AI Analysis
Annual
Quarterly

Whales Holding CNMD

I
Invenomic Capital Management LP
Holding
CNMD
+12.70%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Conmed Corp (CNMD) stock price today?

The current price of CNMD is 36.76 USD — it has decreased -3.52

What is Conmed Corp (CNMD)'s business?

CONMED Corporation is a medical technology company, which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.

What is the price predicton of CNMD Stock?

Wall Street analysts forecast CNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNMD is50.00 USD with a low forecast of 41.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Conmed Corp (CNMD)'s revenue for the last quarter?

Conmed Corp revenue for the last quarter amounts to 317.05M USD, decreased -1.31

What is Conmed Corp (CNMD)'s earnings per share (EPS) for the last quarter?

Conmed Corp. EPS for the last quarter amounts to 0.45 USD, increased 136.84

How many employees does Conmed Corp (CNMD). have?

Conmed Corp (CNMD) has 3900 emplpoyees as of May 11 2026.

What is Conmed Corp (CNMD) market cap?

Today CNMD has the market capitalization of 1.11B USD.